Renal Safety Evaluation After Dotarem®-Enhanced MRI
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
Although there is a well documented risk of acute renal failure with the iodinated contrast
agents, the implication of intravenous gadolinium-based contrast agents in nephrotoxicity
remains controversial. The aim of this study was to evaluate the safety profile of gadoterate
meglumine (Dotarem®) in patients with chronic renal insufficiency by evaluating the rate of
patients experiencing contrast-induced nephrotoxicity following the injection of gadoterate
meglumine.